W P Olszynski

Summary

Country: Canada

Publications

  1. pmc Evaluation of easily measured risk factors in the prediction of osteoporotic fractures
    Robert Bensen
    Medical Science, McMaster University, Hamilton, Ontario, Canada
    BMC Musculoskelet Disord 6:47. 2005
  2. ncbi Alendronate for the treatment of osteoporosis in men
    W P Olszynski
    University of Saskatchewan, Saskatoon, SK, Canada
    Expert Opin Pharmacother 9:491-8. 2008
  3. ncbi Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study
    W P Olszynski
    Saskatoon Osteoporosis Centre, Saskatoon, SK, S7K 0H6, Canada
    Osteoporos Int 17:217-24. 2006
  4. ncbi Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment
    Wojciech P Olszynski
    Department of Medicine, University of Saskatchewan, Saskatoon Osteoporosis Centre, Saskatoon, Saskatchewan, Canada
    Clin Ther 26:15-28. 2004
  5. ncbi The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos)
    J D Adachi
    Department of Medicine, St Joseph s Hospital, McMaster University, Charlton Avenue East, Suite 501, L8 N 1Y2 Hamilton, Ontario, Canada
    Osteoporos Int 14:895-904. 2003
  6. doi Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts
    W D Leslie
    Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
    Osteoporos Int 22:1873-83. 2011
  7. ncbi Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study
    D A Hanley
    Department of Medicine, University of Calgary Calgary, Alberta, Canada
    J Bone Miner Res 18:784-90. 2003
  8. ncbi The effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia: a randomized controlled trial
    Mark Lemstra
    College of Medicine, University of Saskatchewan, Saskatoon, Canada
    Clin J Pain 21:166-74. 2005
  9. ncbi Tolerability of risedronate in postmenopausal women intolerant of alendronate
    J D Adachi
    Department of Medicine, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada
    Aging (Milano) 13:347-54. 2001
  10. doi Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
    W P Maksymowych
    Department of Medicine, University of Alberta, Canada
    Ann Rheum Dis 68:948-53. 2009

Collaborators

Detail Information

Publications27

  1. pmc Evaluation of easily measured risk factors in the prediction of osteoporotic fractures
    Robert Bensen
    Medical Science, McMaster University, Hamilton, Ontario, Canada
    BMC Musculoskelet Disord 6:47. 2005
    ..As few premonitory symptoms for fracture exist, it is of critical importance that physicians effectively and efficiently identify individuals at increased fracture risk...
  2. ncbi Alendronate for the treatment of osteoporosis in men
    W P Olszynski
    University of Saskatchewan, Saskatoon, SK, Canada
    Expert Opin Pharmacother 9:491-8. 2008
    ..Men have higher rates of osteoporosis and suffer fragility fractures more often than previously believed. Fracture-related morbidity and mortality in men is substantially higher than in women...
  3. ncbi Effectiveness of alendronate and etidronate in the treatment of osteoporosis in men: a prospective observational study
    W P Olszynski
    Saskatoon Osteoporosis Centre, Saskatoon, SK, S7K 0H6, Canada
    Osteoporos Int 17:217-24. 2006
    ..The effect of these two bisphosphonates on fractures and FN BMD in osteoporotic men is likely positive, but requires further study...
  4. ncbi Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment
    Wojciech P Olszynski
    Department of Medicine, University of Saskatchewan, Saskatoon Osteoporosis Centre, Saskatoon, Saskatchewan, Canada
    Clin Ther 26:15-28. 2004
    ..Osteoporosis and fragility fractures in men account for substantial health care expenditures and decreased quality of life...
  5. ncbi The association between osteoporotic fractures and health-related quality of life as measured by the Health Utilities Index in the Canadian Multicentre Osteoporosis Study (CaMos)
    J D Adachi
    Department of Medicine, St Joseph s Hospital, McMaster University, Charlton Avenue East, Suite 501, L8 N 1Y2 Hamilton, Ontario, Canada
    Osteoporos Int 14:895-904. 2003
    ..06; 95% CI: -0.11, -0.00) for women, and rib fractures (-0.06; 95% CI: -0.12, -0.00) for men. In conclusion, this study demonstrates a negative association between osteoporotic fractures and quality of life in both women and men...
  6. doi Construction and validation of a simplified fracture risk assessment tool for Canadian women and men: results from the CaMos and Manitoba cohorts
    W D Leslie
    Department of Medicine, University of Manitoba, Winnipeg, MB, Canada
    Osteoporos Int 22:1873-83. 2011
    ..A procedure for creating a simplified version of fracture risk assessment tool (FRAX®) is described. Calibration, fracture prediction, and concordance were compared with the full FRAX tool using two large, complementary Canadian datasets...
  7. ncbi Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study
    D A Hanley
    Department of Medicine, University of Calgary Calgary, Alberta, Canada
    J Bone Miner Res 18:784-90. 2003
    ..The importance of these associations for osteoporosis case finding and management require further and prospective studies...
  8. ncbi The effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia: a randomized controlled trial
    Mark Lemstra
    College of Medicine, University of Saskatchewan, Saskatoon, Canada
    Clin J Pain 21:166-74. 2005
    ..To assess the effectiveness of multidisciplinary rehabilitation in the treatment of fibromyalgia in comparison to standard medical care...
  9. ncbi Tolerability of risedronate in postmenopausal women intolerant of alendronate
    J D Adachi
    Department of Medicine, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada
    Aging (Milano) 13:347-54. 2001
    ..These results are consistent with, and complement those from previous studies showing that risedronate 5 mg has a gastrointestinal tolerability similar to that of placebo...
  10. doi Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
    W P Maksymowych
    Department of Medicine, University of Alberta, Canada
    Ann Rheum Dis 68:948-53. 2009
    ..Enthesitis is a recommended core domain for assessment of ankylosing spondylitis (AS), but no measurement has yet been validated according to Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) criteria...
  11. ncbi The influence of motor vehicle legislation on injury claim incidence
    Mark Lemstra
    College of Medicine, University of Saskatchewan, 103 Hospital Drive, Saskatoon, SK S7N 0W8
    Can J Public Health 96:65-8. 2005
    ..In this paper, we examine the role of legislation and compensation system in altering injury claim incidence...
  12. doi Monitoring time interval for pQCT-derived bone outcomes in postmenopausal women
    R L Duckham
    College of Kinesiology, University of Saskatchewan, Saskatoon, SK, Canada
    Osteoporos Int 24:1917-22. 2013
    ....
  13. ncbi The effectiveness of standard care, early intervention, and occupational management in Workers' Compensation claims: part 2
    Mark Lemstra
    College of Medicine, University of Saskatchewan, Saskatoon, Canada
    Spine (Phila Pa 1976) 29:1573-9. 2004
    ..A prospective cohort...
  14. ncbi Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use
    Anthony B Hodsman
    University of Western Ontario, St Joseph s Health Care, Room 2F 15, 268, Grosvenor Street, London, Ontario N6A 4V2, Canada
    Endocr Rev 26:688-703. 2005
    ..At present, concurrent therapy with antiresorptive therapy, particularly bisphosphonates, should be avoided, although sequential therapy with such agents may consolidate the beneficial effects upon the skeleton after PTH is discontinued...
  15. ncbi Are there differences between men and women prescribed bisphosphonate therapy in canadian subspecialty osteoporosis practices?
    Anna M Sawka
    McMaster University, St Joseph s Healthcare, Centre for Evaluation of Medicines, Hamilton, Ontario, Canada
    J Rheumatol 31:1993-5. 2004
    ..To determine if there are differences between men and women referred for treatment of osteoporosis in Canada...
  16. ncbi Are oral bisphosphonates effective in improving lumbar bone mineral density in breast cancer survivors with osteopenia or osteoporosis?
    Anna M Sawka
    Department of Medicine, St Joseph s Healthcare and McMaster University, Hamilton ON
    J Obstet Gynaecol Can 27:759-64. 2005
    ....
  17. pmc Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents
    Claudie Berger
    CaMos Methods Centre, McGill University, Montreal, Que
    CMAJ 178:1660-8. 2008
    ..We sought to estimate the average rate of change in bone mineral density as a function of age among Canadians aged 25-85, stratified by sex and use of antiresorptive agents...
  18. ncbi Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database
    Alexandra Papaioannou
    Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    Osteoporos Int 14:808-13. 2003
    ..In conclusion, alendronate users were more likely to discontinue therapy than etidronate users over the follow-up period. Potential barriers to long-term patient adherence to osteoporosis therapies need to be evaluated...
  19. ncbi What predicts early fracture or bone loss on bisphosphonate therapy?
    Anna M Sawka
    McMaster University, Hamilton, ON, CA
    J Clin Densitom 6:315-22. 2003
    ..13, 0.62, p = 0.002). In conclusion, early fracture on bisphosphonate therapy is most strongly predicted by a previous history of fracture and early bone loss is most strongly predicted by the potency of the prescribed bisphosphonate...
  20. pmc The 2002 Canadian bone densitometry recommendations: take-home messages
    Aliya A Khan
    Division of Geriatrics, McMaster University, Hamilton, ON
    CMAJ 167:1141-5. 2002
  21. doi Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD Official Positions
    Marc Antoine Krieg
    Lausanne University Hospital, Lausanne, Switzerland
    J Clin Densitom 11:163-87. 2008
    ..The ISCD Official Positions on QUS resulting from this PDC, the rationale for their establishment, and recommendations for further study are presented here...
  22. pmc Management of osteoporosis in men: an update and case example
    Aliya A Khan
    Division of Endocrinology and Geriatrics, Department of Medicine, McMaster University, Hamilton, Ont
    CMAJ 176:345-8. 2007
    ..The current paper supplements that guideline and provides a review and synthesis of the current literature on the diagnosis and management of osteoporosis in men...
  23. ncbi Bone strength: the whole is greater than the sum of its parts
    K Shawn Davison
    Clinical Research Scientist, Department of Medicine, Laval University, Sainte Foy, Quebec, Canada
    Semin Arthritis Rheum 36:22-31. 2006
    ..To summarize the current knowledge regarding the various determinants of bone strength...
  24. ncbi The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future
    K Shawn Davison
    Clinical Research Scientist, Department of Medicine, Laval University, Sainte Foy, Quebec, Canada
    Semin Arthritis Rheum 36:10-21. 2006
    ..To summarize the current knowledge regarding the impact of the most common antifracture medications on the various determinants of bone strength...
  25. ncbi Standards for performing DXA in individuals with secondary causes of osteoporosis
    Aliya A Khan
    Division of Endocrinology, McMaster University, Hamilton, Ontario, Canada, and Hanover General Hospital, PA, USA
    J Clin Densitom 9:47-57. 2006
    ..Dual-energy X-ray absorptiometry is a valuable tool in assessing skeletal health in individuals with secondary causes of osteoporosis...
  26. ncbi Standards and guidelines for performing central dual-energy x-ray absorptiometry in premenopausal women, men, and children
    Aliya A Khan
    Divisions of Endocrinology and Geriatrics, McMaster University, Hamilton, ON, Canada
    J Clin Densitom 7:51-64. 2004
    ..Previously, this group addressed the performance of densitometry in postmenopausal women. This report addresses the use of densitometry in men, premenopausal women, and children with a focus on dual-energy X-ray absorptiometry...
  27. ncbi Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos)
    Alexandra Papaioannou
    Department of Medicine, St Joseph s Hospital, McMaster University, Hamilton, Ontario, Canada
    Osteoporos Int 16:568-78. 2005
    ..Furthermore, various anthropometric measures, disease conditions, and medications are associated with a new fracture. Identifying postmenopausal women at risk is important given that fracture prevention therapies are now available...